mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2022-13-3-93-106mvjr-1501Research ArticleЭНДОКРИНОЛОГИЯENDOCRYNOLOGYГлюкокортикоидная терапия — фактор риска сердечно-сосудистых заболеванийGlucocorticoid therapy is a risk factor for cardiovascular diseaseshttps://orcid.org/0000-0003-3002-9595ДжериеваИ. С.DzherievaI. S.

Джериева Ирина Саркисовна – доктор медицинских наук, доцент, профессор кафедры внутренних болезней №3.

Ростов-на-Дону.

Irina S. Dzherieva - Dr. Sci. (Med.), Docent, Professor of Department of internal medicine №3, Rostov State Medical University.

Rostov-on-Don.

dgerieva@yandex.ruhttps://orcid.org/0000-0003-4874-7835ВолковаН. И.VolkovaN. I.

Волкова Наталья Ивановна - доктор медицинских наук, профессор, заведующий кафедрой внутренних болезней №3.

Ростов-на-Дону.

Natalya I. Volkova - Dr. Sci. (Med.), Professor, head of Department of internal medicine №3, Rostov State Medical University.

Rostov-on-Don.

n_i_volkova@mail.ruhttps://orcid.org/0000-0002-8690-681XДавиденкоИ. Ю.DavidenkoI. Y.

Давиденко Илья Юрьевич – кандидат медицинских наук, доцент кафедры внутренних болезней №3.

Ростов-на-Дону.

Ilya Y. Davidenko - PhD, Docent of Department of internal medicine №3, Rostov State Medical University.

Rostov-on-Don.

davidenko.iu@gmail.comhttps://orcid.org/0000-0003-3445-322XРешетниковИ. Б.ReshetnikovI. B.

Решетников Игорь Борисович - ассистент кафедры внутренних болезней №3.

Ростов-на-Дону.

Igor B. Reshetnikov - MD, Assistant of professor of Department of internal medicine №3, Rostov State Medical University.

Rostov-on-Don.

reshetnikov_ib@rostgmu.ruhttps://orcid.org/0000-0002-2486-5223БровкинаС. С.BrovkinaS. S.

Бровкина Снежана Сергеевна - аспирант кафедры внутренних болезней №3.

Ростов-на-Дону.

SPIN-код: 3059-0330

Snezhana S. Brovkina - MD, PhD student of Department of internal medicine №3, Rostov State Medical University.

Rostov-on-Don.

snegka12345@ya.ruАваковаС. М.AvakovaS. M.

Авакова Софья Михайловна - ординатор кафедры внутренних болезней №3.

Ростов-на-Дону.

Sofia M. Avakova - Rostov State Medical University, Department of internal medicine №3.

Rostov-on-Don.

sm-avakova@mail.ruТищенкоЮ. В.TishchenkoY. V.

Тищенко Юлия Валерьевна - студентка 5 курса педиатрического факультета.

Ростов-на-Дону.

Yulia V. Tishchenko - Rostov State Medical University, Department of internal medicine №3.

Rostov-on-Don.

yulia.tishenko@mail.ruРостовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation20223009202213393106Copyright © Джериева И.С., Волкова Н.И., Давиденко И.Ю., Решетников И.Б., Бровкина С.С., Авакова С.М., Тищенко Ю.В., 20222022Джериева И.С., Волкова Н.И., Давиденко И.Ю., Решетников И.Б., Бровкина С.С., Авакова С.М., Тищенко Ю.В.Dzherieva I.S., Volkova N.I., Davidenko I.Y., Reshetnikov I.B., Brovkina S.S., Avakova S.M., Tishchenko Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1501

Глюкокортикоиды (ГК) являются одними из самых распространённых препаратов в практике врачей различных специальностей благодаря их терапевтическим эффектам. Возросшее количество случаев использования связано с текущей пандемией вируса SARS-CoV-2. Однако ГК-терапия имеет серьёзные ограничения в виде побочных эффектов, в том числе приводящих к фатальным исходам. К побочным явлениям относят нарушение углеводного и липидного обменов, увеличение массы тела, нарушения сна, тромбоэмболию, атеросклеротические изменения, остеопороз, миопатию и др. Описанные процессы обусловливают непосредственное увеличение риска развития сердечно-сосудистых заболеваний (ССЗ) даже на фоне непродолжительной терапии низкими дозами ГК, что отражается на дальнейшей жизни, прогнозе и исходах основного заболевания. В настоящем обзоре подробно рассмотрены патогенетические механизмы и взаимное влияние побочных эффектов ГК, их вклад в последующее возникновение ССЗ и сделан акцент на опасности нерационального применения ГК терапии.

Glucocorticoids (GC) are one of the most common drugs in the practice of doctors of various specialties because of their therapeutic effects. The increased number of usage is related to the current SARS-CoV-2 virus pandemic. However, GC therapy has serious obstacles caused by side effects, including those leading to fatal outcomes. Side effects include: glucose and lipid metabolism impairments, weight gain, sleep disorders, thromboembolism, atherosclerosis, osteoporosis, myopathy, etc. The described processes cause a direct increase in the risk of developing cardiovascular diseases (CVD) even with short-term therapy and low doses of GC, which affects the further life, prognosis and outcomes of the underlying disease. This review describes in detail the pathogenetic mechanisms and the mutual influence of the side effects of GC, their contribution to the subsequent occurrence of CVD and focuses on the danger of irrational use of GC therapy.

глюкокортикоидыпобочные эффектысердечно-сосудистые заболеванияобзорglucocorticoidsside effectscardiovascular diseasesreviewReferencesLaugesen K, Jørgensen JOL, Petersen I, Sørensen HT. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. Eur J Endocrinol. 2019;181(3):267-273. DOI: 10.1530/EJE-19-0305.Laugesen K, Jørgensen JOL, Petersen I, Sørensen HT. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. Eur J Endocrinol. 2019;181(3):267-273. DOI: 10.1530/EJE-19-0305.Bénard-Laribière A, Pariente A, Pambrun E, Bégaud B, Fardet L, Noize P. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France. BMJ Open. 2017;7(7):e015905. DOI: 10.1136/bmjopen-2017-015905Bénard-Laribière A, Pariente A, Pambrun E, Bégaud B, Fardet L, Noize P. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France. BMJ Open. 2017;7(7):e015905. DOI: 10.1136/bmjopen-2017-015905Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019;10:1545. DOI: 10.3389/fimmu.2019.01545Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019;10:1545. DOI: 10.3389/fimmu.2019.01545Тодосенко Н.М., Королева Ю.А., Хазиахматова О.Г., Юрова К.А., Литвинова Л.С. Геномные и негеномные эффекты глюкокортикоидов. Гены и клетки. 2017;12(1): 27-33. DOI: 10.23868/201703003Тодосенко Н.М., Королева Ю.А., Хазиахматова О.Г., Юрова К.А., Литвинова Л.С. Геномные и негеномные эффекты глюкокортикоидов. Гены и клетки. 2017;12(1): 27-33. DOI: 10.23868/201703003Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952-7. DOI: 10.1136/annrheumdis-2015-208916Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952-7. DOI: 10.1136/annrheumdis-2015-208916Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Med. 2020;17(12):e1003432. DOI: 10.1371/journal.pmed.1003432Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Med. 2020;17(12):e1003432. DOI: 10.1371/journal.pmed.1003432Roubille C, Coffy A, Rincheval N, Dougados M, Flipo RM, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2021;60(8):3738-3746. DOI: 10.1093/rheumatology/keaa850.Roubille C, Coffy A, Rincheval N, Dougados M, Flipo RM, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2021;60(8):3738-3746. DOI: 10.1093/rheumatology/keaa850.Wilkinson L, Verhoog NJD, Louw A. Disease- and treatment-associated acquired glucocorticoid resistance. Endocr Connect. 2018;7(12):R328-R349. DOI: 10.1530/EC-18-0421Wilkinson L, Verhoog NJD, Louw A. Disease- and treatment-associated acquired glucocorticoid resistance. Endocr Connect. 2018;7(12):R328-R349. DOI: 10.1530/EC-18-0421Rog-Zielinska EA, Thomson A, Kenyon CJ, Brownstein DG, Moran CM, et al Glucocorticoid receptor is required for foetal heart maturation. Hum Mol Genet. 2013;22(16):3269-82. DOI: 10.1093/hmg/ddt182Rog-Zielinska EA, Thomson A, Kenyon CJ, Brownstein DG, Moran CM, et al Glucocorticoid receptor is required for foetal heart maturation. Hum Mol Genet. 2013;22(16):3269-82. DOI: 10.1093/hmg/ddt182Oakley RH, Ren R, Cruz-Topete D, Bird GS, Myers PH, et al. Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. Proc Natl Acad Sci U S A. 2013;110(42):17035-40. DOI: 10.1073/pnas.1302546110.Oakley RH, Ren R, Cruz-Topete D, Bird GS, Myers PH, et al. Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. Proc Natl Acad Sci U S A. 2013;110(42):17035-40. DOI: 10.1073/pnas.1302546110.Richardson RV, Batchen EJ, Thomson AJ, Darroch R, Pan X, et al. Glucocorticoid receptor alters isovolumetric contraction and restrains cardiac fibrosis. J Endocrinol. 2017;232(3):437-450. DOI: 10.1530/JOE-16-0458.Richardson RV, Batchen EJ, Thomson AJ, Darroch R, Pan X, et al. Glucocorticoid receptor alters isovolumetric contraction and restrains cardiac fibrosis. J Endocrinol. 2017;232(3):437-450. DOI: 10.1530/JOE-16-0458.Peng J, Zhou Y, Zhang Z, Wang Z, Gao L, et al. The detrimental effects of glucocorticoids exposure during pregnancy on offspring's cardiac functions mediated by hypermethylation of bone morphogenetic protein-4. Cell Death Dis. 2018;9(8):834. DOI: 10.1038/s41419-018-0841-1.Peng J, Zhou Y, Zhang Z, Wang Z, Gao L, et al. The detrimental effects of glucocorticoids exposure during pregnancy on offspring's cardiac functions mediated by hypermethylation of bone morphogenetic protein-4. Cell Death Dis. 2018;9(8):834. DOI: 10.1038/s41419-018-0841-1.Agnew EJ, Ivy JR, Stock SJ, Chapman KE. Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation. J Mol Endocrinol. 2018;61(1):R61-R73. DOI: 10.1530/JME-18-0077.Agnew EJ, Ivy JR, Stock SJ, Chapman KE. Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation. J Mol Endocrinol. 2018;61(1):R61-R73. DOI: 10.1530/JME-18-0077.Eberle C, Fasig T, Brüseke F, Stichling S. Impact of maternal prenatal stress by glucocorticoids on metabolic and cardiovascular outcomes in their offspring: A systematic scoping review. PLoS One. 2021;16(1):e0245386. DOI: 10.1371/journal.pone.0245386.Eberle C, Fasig T, Brüseke F, Stichling S. Impact of maternal prenatal stress by glucocorticoids on metabolic and cardiovascular outcomes in their offspring: A systematic scoping review. PLoS One. 2021;16(1):e0245386. DOI: 10.1371/journal.pone.0245386.Burgueño AL, Juárez YR, Genaro AM, Tellechea ML. Prenatal stress and later metabolic consequences: Systematic review and meta-analysis in rodents. Psychoneuroendocrinology. 2020;113:104560. DOI: 10.1016/j.psyneuen.2019.104560.Burgueño AL, Juárez YR, Genaro AM, Tellechea ML. Prenatal stress and later metabolic consequences: Systematic review and meta-analysis in rodents. Psychoneuroendocrinology. 2020;113:104560. DOI: 10.1016/j.psyneuen.2019.104560.Lamichhane N, Olsen NJ, Mortensen EL, Obel C, Heitmann BL, Händel MN. Associations between maternal stress during pregnancy and offspring obesity risk later in life-A systematic literature review. Obes Rev. 2020;21(2):e12951. DOI: 10.1111/obr.12951.Lamichhane N, Olsen NJ, Mortensen EL, Obel C, Heitmann BL, Händel MN. Associations between maternal stress during pregnancy and offspring obesity risk later in life-A systematic literature review. Obes Rev. 2020;21(2):e12951. DOI: 10.1111/obr.12951.Song R, Hu XQ, Zhang L. Glucocorticoids and programming of the microenvironment in heart. J Endocrinol. 2019;242(1):T121-T133. DOI: 10.1530/JOE-18-0672.Song R, Hu XQ, Zhang L. Glucocorticoids and programming of the microenvironment in heart. J Endocrinol. 2019;242(1):T121-T133. DOI: 10.1530/JOE-18-0672.Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2(6):608-15. DOI: 10.1161/CIRCHEARTFAILURE.109.868513.Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2(6):608-15. DOI: 10.1161/CIRCHEARTFAILURE.109.868513.Ronaldson A, Kidd T, Poole L, Leigh E, Jahangiri M, Steptoe A. Diurnal Cortisol Rhythm Is Associated With Adverse Cardiac Events and Mortality in Coronary Artery Bypass Patients. J Clin Endocrinol Metab. 2015;100(10):3676-82. DOI: 10.1210/jc.2015-2617.Ronaldson A, Kidd T, Poole L, Leigh E, Jahangiri M, Steptoe A. Diurnal Cortisol Rhythm Is Associated With Adverse Cardiac Events and Mortality in Coronary Artery Bypass Patients. J Clin Endocrinol Metab. 2015;100(10):3676-82. DOI: 10.1210/jc.2015-2617.Hammer F, Deutschbein T, Marx A, Güder G, Michalski R, et al. High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. Int J Cardiol. 2016;203:69-73. DOI: 10.1016/j.ijcard.2015.10.084.Hammer F, Deutschbein T, Marx A, Güder G, Michalski R, et al. High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. Int J Cardiol. 2016;203:69-73. DOI: 10.1016/j.ijcard.2015.10.084.Caulfield JI, Cavigelli SA. Individual differences in glucocorticoid regulation: Does it relate to disease risk and resilience? Front Neuroendocrinol. 2020;56:100803. DOI: 10.1016/j.yfrne.2019.100803.Caulfield JI, Cavigelli SA. Individual differences in glucocorticoid regulation: Does it relate to disease risk and resilience? Front Neuroendocrinol. 2020;56:100803. DOI: 10.1016/j.yfrne.2019.100803.Song H, Fang F, Arnberg FK, Mataix-Cols D, Fernández de la Cruz L, et al. Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. BMJ. 2019;365:l1255. DOI: 10.1136/bmj.l1255.Song H, Fang F, Arnberg FK, Mataix-Cols D, Fernández de la Cruz L, et al. Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. BMJ. 2019;365:l1255. DOI: 10.1136/bmj.l1255.Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101521. DOI: 10.1016/j.beem.2021.101521.Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101521. DOI: 10.1016/j.beem.2021.101521.Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO. Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010;92 Suppl 1:1-5. DOI: 10.1159/000314297.Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO. Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010;92 Suppl 1:1-5. DOI: 10.1159/000314297.Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96(3):632-42. DOI: 10.1210/jc.2010-1942.Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96(3):632-42. DOI: 10.1210/jc.2010-1942.Webb SM, Valassi E. Morbidity of Cushing's Syndrome and Impact of Treatment. Endocrinol Metab Clin North Am. 2018;47(2):299-311. DOI: 10.1016/j.ecl.2018.01.001.Webb SM, Valassi E. Morbidity of Cushing's Syndrome and Impact of Treatment. Endocrinol Metab Clin North Am. 2018;47(2):299-311. DOI: 10.1016/j.ecl.2018.01.001.Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527-33. DOI: 10.1210/jc.2002-021558.Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527-33. DOI: 10.1210/jc.2002-021558.Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84(8):2664-72. DOI: 10.1210/jcem.84.8.5896.Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84(8):2664-72. DOI: 10.1210/jcem.84.8.5896.Aranda G, Fernandez-Ruiz R, Palomo M, Romo M, Mora M, et al. Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission. Clin Endocrinol (Oxf). 2018;88(3):415-424. DOI: 10.1111/cen.13521.Aranda G, Fernandez-Ruiz R, Palomo M, Romo M, Mora M, et al. Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission. Clin Endocrinol (Oxf). 2018;88(3):415-424. DOI: 10.1111/cen.13521.Sarabdjitsingh RA, Isenia S, Polman A, Mijalkovic J, Lachize S, et al. Disrupted corticosterone pulsatile patterns attenuate responsiveness to glucocorticoid signaling in rat brain. Endocrinology. 2010;151(3):1177-86. DOI: 10.1210/en.2009-1119.Sarabdjitsingh RA, Isenia S, Polman A, Mijalkovic J, Lachize S, et al. Disrupted corticosterone pulsatile patterns attenuate responsiveness to glucocorticoid signaling in rat brain. Endocrinology. 2010;151(3):1177-86. DOI: 10.1210/en.2009-1119.Skov J, Sundström A, Ludvigsson JF, Kämpe O, Bensing S. Sex-Specific Risk of Cardiovascular Disease in Autoimmune Addison Disease-A Population-Based Cohort Study. J Clin Endocrinol Metab. 2019;104(6):2031-2040. DOI: 10.1210/jc.2018-02298.Skov J, Sundström A, Ludvigsson JF, Kämpe O, Bensing S. Sex-Specific Risk of Cardiovascular Disease in Autoimmune Addison Disease-A Population-Based Cohort Study. J Clin Endocrinol Metab. 2019;104(6):2031-2040. DOI: 10.1210/jc.2018-02298.Roelfsema F, van Heemst D, Iranmanesh A, Takahashi P, Yang R, Veldhuis JD. Impact of age, sex and body mass index on cortisol secretion in 143 healthy adults. Endocr Connect. 2017;6(7):500-509. DOI: 10.1530/EC-17-0160.Roelfsema F, van Heemst D, Iranmanesh A, Takahashi P, Yang R, Veldhuis JD. Impact of age, sex and body mass index on cortisol secretion in 143 healthy adults. Endocr Connect. 2017;6(7):500-509. DOI: 10.1530/EC-17-0160.Toering TJ, Gant CM, Visser FW, van der Graaf AM, Laverman GD, et al. Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. Am J Physiol Renal Physiol. 2018;314(5):F873-F878. DOI: 10.1152/ajprenal.00109.2017.Toering TJ, Gant CM, Visser FW, van der Graaf AM, Laverman GD, et al. Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. Am J Physiol Renal Physiol. 2018;314(5):F873-F878. DOI: 10.1152/ajprenal.00109.2017.Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157(5):545-59. DOI: 10.1530/EJE-07-0455.Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157(5):545-59. DOI: 10.1530/EJE-07-0455.Lupoli R, Ambrosino P, Tortora A, Barba L, Lupoli GA, Di Minno MN. Markers of atherosclerosis in patients with Cushing's syndrome: a meta-analysis of literature studies. Ann Med. 2017;49(3):206-216. DOI: 10.1080/07853890.2016.1252055.Lupoli R, Ambrosino P, Tortora A, Barba L, Lupoli GA, Di Minno MN. Markers of atherosclerosis in patients with Cushing's syndrome: a meta-analysis of literature studies. Ann Med. 2017;49(3):206-216. DOI: 10.1080/07853890.2016.1252055.Petramala L, Lorenzo D, Iannucci G, Concistré A, Zinnamosca L, et al. Subclinical Atherosclerosis in Patients with Cushing Syndrome: Evaluation with Carotid Intima-Media Thickness and Ankle-Brachial Index. Endocrinol Metab (Seoul). 2015;30(4):488-93. DOI: 10.3803/EnM.2015.30.4.488.Petramala L, Lorenzo D, Iannucci G, Concistré A, Zinnamosca L, et al. Subclinical Atherosclerosis in Patients with Cushing Syndrome: Evaluation with Carotid Intima-Media Thickness and Ankle-Brachial Index. Endocrinol Metab (Seoul). 2015;30(4):488-93. DOI: 10.3803/EnM.2015.30.4.488.van der Sluis RJ, Hoekstra M. Glucocorticoids are active players and therapeutic targets in atherosclerotic cardiovascular disease. Mol Cell Endocrinol. 2020;504:110728. DOI: 10.1016/j.mce.2020.110728.van der Sluis RJ, Hoekstra M. Glucocorticoids are active players and therapeutic targets in atherosclerotic cardiovascular disease. Mol Cell Endocrinol. 2020;504:110728. DOI: 10.1016/j.mce.2020.110728.Asai K, Funaki C, Hayashi T, Yamada K, Naito M, et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb. 1993;13(6):892-9. DOI: 10.1161/01.atv.13.6.892.Asai K, Funaki C, Hayashi T, Yamada K, Naito M, et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb. 1993;13(6):892-9. DOI: 10.1161/01.atv.13.6.892.Auvinen HE, Wang Y, Princen H, Romijn JA, Havekes LM, et al. Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP mice. PLoS One. 2013;8(5):e63882. DOI: 10.1371/journal.pone.0063882.Auvinen HE, Wang Y, Princen H, Romijn JA, Havekes LM, et al. Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP mice. PLoS One. 2013;8(5):e63882. DOI: 10.1371/journal.pone.0063882.Jeries H, Volkova N, Grajeda-Iglesias C, Najjar M, Rosenblat M, et al. Prednisone and Its Active Metabolite Prednisolone Attenuate Lipid Accumulation in Macrophages. J Cardiovasc Pharmacol Ther. 2020;25(2):174-186. DOI: 10.1177/1074248419883591.Jeries H, Volkova N, Grajeda-Iglesias C, Najjar M, Rosenblat M, et al. Prednisone and Its Active Metabolite Prednisolone Attenuate Lipid Accumulation in Macrophages. J Cardiovasc Pharmacol Ther. 2020;25(2):174-186. DOI: 10.1177/1074248419883591.Deuchar GA, McLean D, Hadoke PWF, Brownstein DG, Webb DJ, et al. 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology. 2011;152(1):236-246. DOI: 10.1210/en.2010-0925.Deuchar GA, McLean D, Hadoke PWF, Brownstein DG, Webb DJ, et al. 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology. 2011;152(1):236-246. DOI: 10.1210/en.2010-0925.García RA, Search DJ, Lupisella JA, Ostrowski J, Guan B, et al. 11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice. PLoS One. 2013;8(2):e53192. DOI: 10.1371/journal.pone.0053192.García RA, Search DJ, Lupisella JA, Ostrowski J, Guan B, et al. 11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice. PLoS One. 2013;8(2):e53192. DOI: 10.1371/journal.pone.0053192.Roubert P, Viossat I, Lonchampt MO, Chapelat M, Schulz J, et al. Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon. J Vasc Res. 1993;30(3):139-44. DOI: 10.1159/000158988.Roubert P, Viossat I, Lonchampt MO, Chapelat M, Schulz J, et al. Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon. J Vasc Res. 1993;30(3):139-44. DOI: 10.1159/000158988.Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8(5):473-9. DOI: 10.1038/nm0502-473.Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8(5):473-9. DOI: 10.1038/nm0502-473.Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27(7):1059-66. DOI: 10.1007/s00467-011-1928-4.Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27(7):1059-66. DOI: 10.1007/s00467-011-1928-4.Masi S, Uliana M, Gesi M, Taddei S, Virdis A. Drug-induced hypertension: Know the problem to know how to deal with it. Vascul Pharmacol. 2019;115:84-88. DOI: 10.1016/j.vph.2019.02.002.Masi S, Uliana M, Gesi M, Taddei S, Virdis A. Drug-induced hypertension: Know the problem to know how to deal with it. Vascul Pharmacol. 2019;115:84-88. DOI: 10.1016/j.vph.2019.02.002.Barbot M, Ceccato F, Scaroni C. The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. Front Endocrinol (Lausanne). 2019;10:321. DOI: 10.3389/fendo.2019.00321.Barbot M, Ceccato F, Scaroni C. The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. Front Endocrinol (Lausanne). 2019;10:321. DOI: 10.3389/fendo.2019.00321.MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers? Int J Mol Sci. 2021;22(14):7622. DOI: 10.3390/ijms22147622.MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers? Int J Mol Sci. 2021;22(14):7622. DOI: 10.3390/ijms22147622.Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728-9. DOI: 10.2337/dc06-1499.Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728-9. DOI: 10.2337/dc06-1499.Beaupere C, Liboz A, Fève B, Blondeau B, Guillemain G. Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance. Int J Mol Sci. 2021;22(2):623. doi: 10.3390/ijms22020623.Beaupere C, Liboz A, Fève B, Blondeau B, Guillemain G. Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance. Int J Mol Sci. 2021;22(2):623. doi: 10.3390/ijms22020623.Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-6. DOI: 10.1002/art.21984.Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-6. DOI: 10.1002/art.21984.Reich E, Tamary A, Sionov RV, Melloul D. Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death. Diabetologia. 2012;55(4):1048-57. DOI: 10.1007/s00125-011-2422-z.Reich E, Tamary A, Sionov RV, Melloul D. Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death. Diabetologia. 2012;55(4):1048-57. DOI: 10.1007/s00125-011-2422-z.Guo B, Zhang W, Xu S, Lou J, Wang S, Men X. GSK-3β mediates dexamethasone-induced pancreatic β cell apoptosis. Life Sci. 2016;144:1-7. DOI: 10.1016/j.lfs.2015.11.017.Guo B, Zhang W, Xu S, Lou J, Wang S, Men X. GSK-3β mediates dexamethasone-induced pancreatic β cell apoptosis. Life Sci. 2016;144:1-7. DOI: 10.1016/j.lfs.2015.11.017.Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54(4):1090-9. DOI: 10.2337/diabetes.54.4.1090.Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54(4):1090-9. DOI: 10.2337/diabetes.54.4.1090.Fine NHF, Doig CL, Elhassan YS, Vierra NC, Marchetti P, et al. Glucocorticoids Reprogram β-Cell Signaling to Preserve Insulin Secretion. Diabetes. 2018;67(2):278-290. DOI: 10.2337/db16-1356.Fine NHF, Doig CL, Elhassan YS, Vierra NC, Marchetti P, et al. Glucocorticoids Reprogram β-Cell Signaling to Preserve Insulin Secretion. Diabetes. 2018;67(2):278-290. DOI: 10.2337/db16-1356.Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR. High doses of dexamethasone induce increased beta-cell proliferation in pancreatic rat islets. Am J Physiol Endocrinol Metab. 2009;296(4):E681-9. DOI: 10.1152/ajpendo.90931.2008.Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR. High doses of dexamethasone induce increased beta-cell proliferation in pancreatic rat islets. Am J Physiol Endocrinol Metab. 2009;296(4):E681-9. DOI: 10.1152/ajpendo.90931.2008.Rafacho A, Abrantes JL, Ribeiro DL, Paula FM, Pinto ME, et al. Morphofunctional alterations in endocrine pancreas of short- and long-term dexamethasone-treated rats. Horm Metab Res. 2011;43(4):275-81. DOI: 10.1055/s-0030-1269896.Rafacho A, Abrantes JL, Ribeiro DL, Paula FM, Pinto ME, et al. Morphofunctional alterations in endocrine pancreas of short- and long-term dexamethasone-treated rats. Horm Metab Res. 2011;43(4):275-81. DOI: 10.1055/s-0030-1269896.Courty E, Besseiche A, Do TTH, Liboz A, Aguid FM, et al. Adaptive β-Cell Neogenesis in the Adult Mouse in Response to Glucocorticoid-Induced Insulin Resistance. Diabetes. 2019;68(1):95-108. DOI: 10.2337/db17-1314.Courty E, Besseiche A, Do TTH, Liboz A, Aguid FM, et al. Adaptive β-Cell Neogenesis in the Adult Mouse in Response to Glucocorticoid-Induced Insulin Resistance. Diabetes. 2019;68(1):95-108. DOI: 10.2337/db17-1314.Riveline JP, Baz B, Nguewa JL, Vidal-Trecan T, Ibrahim F, et al. Exposure to Glucocorticoids in the First Part of Fetal Life is Associated with Insulin Secretory Defect in Adult Humans. J Clin Endocrinol Metab. 2020;105(3):dgz145. DOI: 10.1210/clinem/dgz145.Riveline JP, Baz B, Nguewa JL, Vidal-Trecan T, Ibrahim F, et al. Exposure to Glucocorticoids in the First Part of Fetal Life is Associated with Insulin Secretory Defect in Adult Humans. J Clin Endocrinol Metab. 2020;105(3):dgz145. DOI: 10.1210/clinem/dgz145.Do TTH, Marie G, Héloïse D, Guillaume D, Marthe M, et al. Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration. J Steroid Biochem Mol Biol. 2019;185:150-162. DOI: 10.1016/j.jsbmb.2018.08.010.Do TTH, Marie G, Héloïse D, Guillaume D, Marthe M, et al. Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration. J Steroid Biochem Mol Biol. 2019;185:150-162. DOI: 10.1016/j.jsbmb.2018.08.010.Campbell JE, Peckett AJ, D'souza AM, Hawke TJ, Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol. 2011;300(1):C198-209. DOI: 10.1152/ajpcell.00045.2010.Campbell JE, Peckett AJ, D'souza AM, Hawke TJ, Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol. 2011;300(1):C198-209. DOI: 10.1152/ajpcell.00045.2010.Dalle H, Garcia M, Antoine B, Boehm V, Do TTH, et al. Adipocyte Glucocorticoid Receptor Deficiency Promotes Adipose Tissue Expandability and Improves the Metabolic Profile Under Corticosterone Exposure. Diabetes. 2019;68(2):305-317. DOI: 10.2337/db17-1577.Dalle H, Garcia M, Antoine B, Boehm V, Do TTH, et al. Adipocyte Glucocorticoid Receptor Deficiency Promotes Adipose Tissue Expandability and Improves the Metabolic Profile Under Corticosterone Exposure. Diabetes. 2019;68(2):305-317. DOI: 10.2337/db17-1577.Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta. 2014;1842(3):473-81. DOI: 10.1016/j.bbadis.2013.05.029.Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta. 2014;1842(3):473-81. DOI: 10.1016/j.bbadis.2013.05.029.Marcondes-de-Mello ML, Serafim-Costa MC, Alves-E-Silva MM, Oliveira NR, Bertolucci-Caldo NV, et al. Effect of glucocorticoids on glyceroneogenesis in adipose tissue: A systematic review. Biochimie. 2020;168:210-219. DOI: 10.1016/j.biochi.2019.11.007.Marcondes-de-Mello ML, Serafim-Costa MC, Alves-E-Silva MM, Oliveira NR, Bertolucci-Caldo NV, et al. Effect of glucocorticoids on glyceroneogenesis in adipose tissue: A systematic review. Biochimie. 2020;168:210-219. DOI: 10.1016/j.biochi.2019.11.007.Lefranc C, Friederich-Persson M, Braud L, Palacios-Ramirez R, Karlsson S, et al. MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity. Hypertension. 2019;73(2):458-468. DOI: 10.1161/HYPERTENSIONAHA.118.11873.Lefranc C, Friederich-Persson M, Braud L, Palacios-Ramirez R, Karlsson S, et al. MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity. Hypertension. 2019;73(2):458-468. DOI: 10.1161/HYPERTENSIONAHA.118.11873.Akalestou E, Genser L, Rutter GA. Glucocorticoid Metabolism in Obesity and Following Weight Loss. Front Endocrinol (Lausanne). 2020;11:59. DOI: 10.3389/fendo.2020.00059.Akalestou E, Genser L, Rutter GA. Glucocorticoid Metabolism in Obesity and Following Weight Loss. Front Endocrinol (Lausanne). 2020;11:59. DOI: 10.3389/fendo.2020.00059.Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-Induced Fatty Liver Disease. Diabetes Metab Syndr Obes. 2020;13:1133-1145. DOI: 10.2147/DMSO.S247379.Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-Induced Fatty Liver Disease. Diabetes Metab Syndr Obes. 2020;13:1133-1145. DOI: 10.2147/DMSO.S247379.Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453-1460. DOI: 10.1172/JCI134165.Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453-1460. DOI: 10.1172/JCI134165.Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J. 2004;378(Pt 3):967-74. DOI: 10.1042/BJ20031320.Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J. 2004;378(Pt 3):967-74. DOI: 10.1042/BJ20031320.Marino JS, Stechschulte LA, Stec DE, Nestor-Kalinoski A, Coleman S, Hinds TD Jr. Glucocorticoid Receptor β Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α. J Biol Chem. 2016;291(50):25776-25788. DOI: 10.1074/jbc.M116.752311.Marino JS, Stechschulte LA, Stec DE, Nestor-Kalinoski A, Coleman S, Hinds TD Jr. Glucocorticoid Receptor β Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α. J Biol Chem. 2016;291(50):25776-25788. DOI: 10.1074/jbc.M116.752311.Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8(2):51-58. DOI: 10.4291/wjgp.v8.i2.51.Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8(2):51-58. DOI: 10.4291/wjgp.v8.i2.51.Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17):3104. DOI: 10.3390/ijerph16173104.Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17):3104. DOI: 10.3390/ijerph16173104.DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S157-63. DOI: 10.2337/dc09-S302.DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S157-63. DOI: 10.2337/dc09-S302.Vestergaard H, Bratholm P, Christensen NJ. Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes. Clin Sci (Lond). 2001;101(5):533-40. DOI: 10.1042/cs1010533.Vestergaard H, Bratholm P, Christensen NJ. Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes. Clin Sci (Lond). 2001;101(5):533-40. DOI: 10.1042/cs1010533.Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes. 2002;51(4):1066-75. DOI: 10.2337/diabetes.51.4.1066.Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes. 2002;51(4):1066-75. DOI: 10.2337/diabetes.51.4.1066.Minetto MA, D'Angelo V, Arvat E, Kesari S. Diagnostic work-up in steroid myopathy. Endocrine. 2018;60(2):219-223. DOI: 10.1007/s12020-017-1472-5Minetto MA, D'Angelo V, Arvat E, Kesari S. Diagnostic work-up in steroid myopathy. Endocrine. 2018;60(2):219-223. DOI: 10.1007/s12020-017-1472-5Haran M, Schattner A, Kozak N, Mate A, Berrebi A, Shvidel L. Acute steroid myopathy: a highly overlooked entity. QJM. 2018;111(5):307-311. DOI: 10.1093/qjmed/hcy031.Haran M, Schattner A, Kozak N, Mate A, Berrebi A, Shvidel L. Acute steroid myopathy: a highly overlooked entity. QJM. 2018;111(5):307-311. DOI: 10.1093/qjmed/hcy031.Sato AY, Peacock M, Bellido T. Glucocorticoid excess in bone and muscle. Clin Rev Bone Miner Metab. 2018;16(1):33-47. DOI: 10.1007/s12018-018-9242-3.Sato AY, Peacock M, Bellido T. Glucocorticoid excess in bone and muscle. Clin Rev Bone Miner Metab. 2018;16(1):33-47. DOI: 10.1007/s12018-018-9242-3.Bodine SC, Furlow JD. Glucocorticoids and Skeletal Muscle. Adv Exp Med Biol. 2015;872:145-76. DOI: 10.1007/978-1-4939-2895-8_7.Bodine SC, Furlow JD. Glucocorticoids and Skeletal Muscle. Adv Exp Med Biol. 2015;872:145-76. DOI: 10.1007/978-1-4939-2895-8_7.Lopez PD, Nepal P, Akinlonu A, Nekkalapudi D, Kim K, et al. Low Skeletal Muscle Mass Independently Predicts Mortality in Patients with Chronic Heart Failure after an Acute Hospitalization. Cardiology. 2019;142(1):28-36. DOI: 10.1159/000496460.Lopez PD, Nepal P, Akinlonu A, Nekkalapudi D, Kim K, et al. Low Skeletal Muscle Mass Independently Predicts Mortality in Patients with Chronic Heart Failure after an Acute Hospitalization. Cardiology. 2019;142(1):28-36. DOI: 10.1159/000496460.Han J, Kim W. Prognostic implications of trunk muscle mass in liver cirrhosis. Clin Mol Hepatol. 2018;24(3):297-298. DOI: 10.3350/cmh.2018.0069.Han J, Kim W. Prognostic implications of trunk muscle mass in liver cirrhosis. Clin Mol Hepatol. 2018;24(3):297-298. DOI: 10.3350/cmh.2018.0069.Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347-1372. DOI: 10.1007/s40620-020-00840-y.Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347-1372. DOI: 10.1007/s40620-020-00840-y.Tyrovolas S, Panagiotakos D, Georgousopoulou E, Chrysohoou C, Tousoulis D, et al. Skeletal muscle mass in relation to 10 year cardiovascular disease incidence among middle aged and older adults: the ATTICA study. J Epidemiol Community Health. 2020;74(1):26-31. DOI: 10.1136/jech-2019-212268.Tyrovolas S, Panagiotakos D, Georgousopoulou E, Chrysohoou C, Tousoulis D, et al. Skeletal muscle mass in relation to 10 year cardiovascular disease incidence among middle aged and older adults: the ATTICA study. J Epidemiol Community Health. 2020;74(1):26-31. DOI: 10.1136/jech-2019-212268.Lee MJ, Kim EH, Bae SJ, Choe J, Jung CH, et al. Protective role of skeletal muscle mass against progression from metabolically healthy to unhealthy phenotype. Clin Endocrinol (Oxf). 2019;90(1):102-113. DOI: 10.1111/cen.13874.Lee MJ, Kim EH, Bae SJ, Choe J, Jung CH, et al. Protective role of skeletal muscle mass against progression from metabolically healthy to unhealthy phenotype. Clin Endocrinol (Oxf). 2019;90(1):102-113. DOI: 10.1111/cen.13874.Carbone S, Kirkman DL, Garten RS, Rodriguez-Miguelez P, Artero EG, et al. Muscular Strength and Cardiovascular Disease: an updated state-of-the-art narrative review. J Cardiopulm Rehabil Prev. 2020;40(5):302-309. DOI: 10.1097/HCR.0000000000000525.Carbone S, Kirkman DL, Garten RS, Rodriguez-Miguelez P, Artero EG, et al. Muscular Strength and Cardiovascular Disease: an updated state-of-the-art narrative review. J Cardiopulm Rehabil Prev. 2020;40(5):302-309. DOI: 10.1097/HCR.0000000000000525.Ferron M, Lacombe J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch Biochem Biophys. 2014;561:137-46. DOI: 10.1016/j.abb.2014.05.022.Ferron M, Lacombe J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch Biochem Biophys. 2014;561:137-46. DOI: 10.1016/j.abb.2014.05.022.Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy. Endocr Rev. 2018;39(5):519-548. DOI: 10.1210/er.2018-00097.Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy. Endocr Rev. 2018;39(5):519-548. DOI: 10.1210/er.2018-00097.Uddén J, Björntorp P, Arner P, Barkeling B, Meurling L, Rössner S. Effects of glucocorticoids on leptin levels and eating behaviour in women. J Intern Med. 2003;253(2):225-31. DOI: 10.1046/j.1365-2796.2003.01099.x.Uddén J, Björntorp P, Arner P, Barkeling B, Meurling L, Rössner S. Effects of glucocorticoids on leptin levels and eating behaviour in women. J Intern Med. 2003;253(2):225-31. DOI: 10.1046/j.1365-2796.2003.01099.x.Perry RJ, Resch JM, Douglass AM, Madara JC, Rabin-Court A, et al. Leptin's hunger-suppressing effects are mediated by the hypothalamic-pituitary-adrenocortical axis in rodents. Proc Natl Acad Sci U S A. 2019;116(27):13670-13679. DOI: 10.1073/pnas.1901795116.Perry RJ, Resch JM, Douglass AM, Madara JC, Rabin-Court A, et al. Leptin's hunger-suppressing effects are mediated by the hypothalamic-pituitary-adrenocortical axis in rodents. Proc Natl Acad Sci U S A. 2019;116(27):13670-13679. DOI: 10.1073/pnas.1901795116.Patel R, Belousov M, Jani M, Dasgupta N, Winokur C, et al. Frequent discussion of insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. NPJ Digit Med. 2018;1:20177. DOI: 10.1038/s41746-017-0007-z. Erratum in: NPJ Digit Med. 2018;1:28. PMID: 30740536; PMCID: PMC6364798.Patel R, Belousov M, Jani M, Dasgupta N, Winokur C, et al. Frequent discussion of insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. NPJ Digit Med. 2018;1:20177. DOI: 10.1038/s41746-017-0007-z. Erratum in: NPJ Digit Med. 2018;1:28. PMID: 30740536; PMCID: PMC6364798.Venkatram S, Vakde T, Badipatla K, Niazi M, Diaz-Fuentes G. Unusual triad of obstructive sleep apnea, uncontrolled hypertension, and severe hypokalemia due to ectopic adrenocorticotropic secretion. J Bronchology Interv Pulmonol. 2014;21(2):158-61. DOI: 10.1097/LBR.0000000000000060.Venkatram S, Vakde T, Badipatla K, Niazi M, Diaz-Fuentes G. Unusual triad of obstructive sleep apnea, uncontrolled hypertension, and severe hypokalemia due to ectopic adrenocorticotropic secretion. J Bronchology Interv Pulmonol. 2014;21(2):158-61. DOI: 10.1097/LBR.0000000000000060.Zheng B, Yu C, Lv J, Guo Y, Bian Z, et al. Insomnia symptoms and risk of cardiovascular diseases among 0.5 million adults: A 10-year cohort. Neurology. 2019;93(23):e2110-e2120. DOI: 10.1212/WNL.0000000000008581.Zheng B, Yu C, Lv J, Guo Y, Bian Z, et al. Insomnia symptoms and risk of cardiovascular diseases among 0.5 million adults: A 10-year cohort. Neurology. 2019;93(23):e2110-e2120. DOI: 10.1212/WNL.0000000000008581.Джериева И.С., Волкова Н.И., Рапопорт С. И. Мелатонин как регулятор метаболических процессов. Клиническая медицина. 2012;90(10): 27-30. eLIBRARY ID:18756170Dzherieva I.S., Volkova N.I., Rapoport S.I. Melatonin as a regulator of metabolism. Clinical medicine. 2012;90(10):27-39. (In Russ.). eLIBRARY ID:18756170Johnson RM, Vinetz JM. Dexamethasone in the management of covid -19. BMJ. 2020;370:m2648. DOI: 10.1136/bmj.m2648.Johnson RM, Vinetz JM. Dexamethasone in the management of covid -19. BMJ. 2020;370:m2648. DOI: 10.1136/bmj.m2648.Simion C, Campello E, Bensi E, Bellio A, Pontarin A, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. Semin Thromb Hemost. 2021;47(6):654-661. DOI: 10.1055/s-0040-1722270.Simion C, Campello E, Bensi E, Bellio A, Pontarin A, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. Semin Thromb Hemost. 2021;47(6):654-661. DOI: 10.1055/s-0040-1722270.Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci. 2021;17(6):1530-1537. DOI: 10.7150/ijbs.58695.Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci. 2021;17(6):1530-1537. DOI: 10.7150/ijbs.58695.Orsi FA, Lijfering WM, Geersing GJ, Rosendaal FR, Dekkers OM, et al. Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study. Br J Haematol. 2021;193(6):1194-1202. DOI: 10.1111/bjh.17388.Orsi FA, Lijfering WM, Geersing GJ, Rosendaal FR, Dekkers OM, et al. Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study. Br J Haematol. 2021;193(6):1194-1202. DOI: 10.1111/bjh.17388.

The authors declare that there are no conflicts of interest present.